Amgen, Inc. (NASDAQ:AMGN) – Stock analysts at William Blair lifted their Q1 2018 earnings estimates for Amgen in a note issued to investors on Monday. William Blair analyst M. Phipps now expects that the medical research company will post earnings of $3.34 per share for the quarter, up from their prior forecast of $3.33. William Blair also issued estimates for Amgen’s Q2 2018 earnings at $3.53 EPS, Q3 2018 earnings at $3.50 EPS, FY2018 earnings at $13.51 EPS, Q1 2019 earnings at $3.48 EPS, Q2 2019 earnings at $3.56 EPS, Q3 2019 earnings at $3.58 EPS, Q4 2019 earnings at $3.48 EPS and FY2019 earnings at $14.10 EPS.
Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share for the quarter, missing the Zacks’ consensus estimate of $3.03 by ($0.14). The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.84 billion. Amgen had a return on equity of 30.87% and a net margin of 8.66%. The business’s revenue was down 2.7% on a year-over-year basis. During the same period last year, the company posted $2.89 EPS.
Amgen (NASDAQ:AMGN) opened at $189.30 on Tuesday. The company has a market cap of $137,699.44, a price-to-earnings ratio of 73.66, a PEG ratio of 2.35 and a beta of 1.37. Amgen has a twelve month low of $152.16 and a twelve month high of $201.23. The company has a quick ratio of 5.17, a current ratio of 5.49 and a debt-to-equity ratio of 1.35.
Institutional investors have recently made changes to their positions in the company. BDO Wealth Advisors LLC purchased a new stake in shares of Amgen in the 2nd quarter worth about $145,000. Pacer Advisors Inc. lifted its position in shares of Amgen by 10.3% in the 2nd quarter. Pacer Advisors Inc. now owns 25,378 shares of the medical research company’s stock worth $4,371,000 after purchasing an additional 2,362 shares during the period. Buckingham Asset Management LLC lifted its position in shares of Amgen by 18.0% in the 2nd quarter. Buckingham Asset Management LLC now owns 9,374 shares of the medical research company’s stock worth $1,615,000 after purchasing an additional 1,433 shares during the period. Brookstone Capital Management lifted its position in shares of Amgen by 1.4% in the 2nd quarter. Brookstone Capital Management now owns 4,559 shares of the medical research company’s stock worth $785,000 after purchasing an additional 61 shares during the period. Finally, Kings Point Capital Management lifted its position in shares of Amgen by 13.3% in the 2nd quarter. Kings Point Capital Management now owns 13,758 shares of the medical research company’s stock worth $2,370,000 after purchasing an additional 1,611 shares during the period. 79.61% of the stock is owned by institutional investors.
In other news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction on Wednesday, February 14th. The shares were sold at an average price of $174.18, for a total value of $265,624.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.19% of the stock is currently owned by corporate insiders.
Amgen announced that its board has approved a stock buyback program on Thursday, February 1st that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the medical research company to purchase shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its stock is undervalued.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be paid a $1.32 dividend. The ex-dividend date of this dividend is Wednesday, May 16th. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.79%. Amgen’s dividend payout ratio (DPR) is 205.45%.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.